Wright Richard M.

SEC source: 0001646423-25-000007 · form4-11172025_091104.xml · derivative · entry 7

Wright Richard M. · CIK 0001646423 · Former Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,875

Underlying: Common Stock · 15,750 shares

Expires 2032-06-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001646423-25-000007 · form4-11172025_091104.xml · derivative · entry 6

Wright Richard M. · CIK 0001646423 · Former Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,672 shares

Expires 2030-06-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: As of June 18, 2024, the option is fully vested.

SEC source: 0001646423-25-000007 · form4-11172025_091104.xml · derivative · entry 5

Wright Richard M. · CIK 0001646423 · Former Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,876 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: As of June 13, 2022, the option is fully vested.

SEC source: 0001646423-25-000007 · form4-11172025_091104.xml · nonDerivative · entry 4

Wright Richard M. · CIK 0001646423 · Former Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,833

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001646423-25-000007 · form4-11172025_091104.xml · nonDerivative · entry 3

Wright Richard M. · CIK 0001646423 · Former Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,131

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001646423-25-000007 · form4-11172025_091104.xml · nonDerivative · entry 2

Wright Richard M. · CIK 0001646423 · Former Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,381

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001646423-25-000007 · form4-11172025_091104.xml · nonDerivative · entry 1

Wright Richard M. · CIK 0001646423 · Former Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,709

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-017177 · form4-06172024_080608.xml · derivative · entry 1

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-06-13

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001415889-24-015543 · form4-06052024_080641.xml · derivative · entry 8

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,625

Underlying: Common Stock · 18,375 shares

Expires 2032-06-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001415889-24-015543 · form4-06052024_080641.xml · derivative · entry 7

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,531

Underlying: Common Stock · 28,469 shares

Expires 2031-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% vested on June 17, 2022 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001415889-24-015543 · form4-06052024_080641.xml · derivative · entry 6

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,625 shares

Expires 2029-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: As of June 19, 2023, the option is fully vested.

SEC source: 0001415889-24-015543 · form4-06052024_080641.xml · nonDerivative · entry 5

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,833

F2 · kind: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.815 to $34.20 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.815 to $34.20 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.815 to $34.20 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-24-015543 · form4-06052024_080641.xml · nonDerivative · entry 4

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,097

F1 · kind: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.81 to $33.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F1 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.81 to $33.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.81 to $33.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-24-015543 · form4-06052024_080641.xml · nonDerivative · entry 3

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,677

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-015543 · form4-06052024_080641.xml · nonDerivative · entry 2

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,302

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-015543 · form4-06052024_080641.xml · nonDerivative · entry 1

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,833

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-010048 · form4-06202023_080633.xml · derivative · entry 1

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2033-06-15

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001415889-22-008767 · form4-08172022_010827.xml · derivative · entry 3

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,672

Underlying: Common Stock · 15,328 shares

Expires 2030-06-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001415889-22-008767 · form4-08172022_010827.xml · nonDerivative · entry 2

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.35 to $38.31 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001415889-22-008767 · form4-08172022_010827.xml · nonDerivative · entry 1

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,536

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-22-006733 · form4-06172022_010604.xml · derivative · entry 1

Wright Richard M. · CIK 0001646423 · SR. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,000

Underlying: Common Stock · 42,000 shares

Expires 2032-06-16

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-21-006909 · edgar.xml · derivative · entry 1

Wright Richard M. · CIK 0001646423 · Sr. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,000

Underlying: Common Stock · 42,000 shares

Expires 2031-06-17

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 17, 2022 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-20-011996 · edgar.xml · derivative · entry 6

Wright Richard M. · CIK 0001646423 · Sr. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,625

Underlying: Common Stock · 9,375 shares

Expires 2029-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-20-011996 · edgar.xml · derivative · entry 5

Wright Richard M. · CIK 0001646423 · Sr. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,876

Underlying: Common Stock · 11,457 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but was adjusted to reflect the reverse stock split that occurred on February 8, 2019.

F3 · derivative.exercise_date: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

F2 · balance_after: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but was adjusted to reflect the reverse stock split that occurred on February 8, 2019.

SEC source: 0001179110-20-011996 · edgar.xml · nonDerivative · entry 4

Wright Richard M. · CIK 0001646423 · Sr. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208

F1 · balance_after: On February 8, 2019, the Company implemented a one-for-fifteen reverse stock split of the Company's issued and outstanding common stock, resulting in the reporting person's ownership of 208 shares of the Company's common stock.

SEC source: 0001179110-20-011996 · edgar.xml · nonDerivative · entry 3

Wright Richard M. · CIK 0001646423 · Sr. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: On February 8, 2019, the Company implemented a one-for-fifteen reverse stock split of the Company's issued and outstanding common stock, resulting in the reporting person's ownership of 208 shares of the Company's common stock.

SEC source: 0001179110-20-011996 · edgar.xml · nonDerivative · entry 2

Wright Richard M. · CIK 0001646423 · Sr. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208

F1 · balance_after: On February 8, 2019, the Company implemented a one-for-fifteen reverse stock split of the Company's issued and outstanding common stock, resulting in the reporting person's ownership of 208 shares of the Company's common stock.

SEC source: 0001179110-20-011996 · edgar.xml · nonDerivative · entry 1

Wright Richard M. · CIK 0001646423 · Sr. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,665

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but was adjusted to reflect the reverse stock split that occurred on February 8, 2019.

F1 · balance_after: On February 8, 2019, the Company implemented a one-for-fifteen reverse stock split of the Company's issued and outstanding common stock, resulting in the reporting person's ownership of 208 shares of the Company's common stock.

SEC source: 0001179110-20-007593 · edgar.xml · derivative · entry 1

Wright Richard M. · CIK 0001646423 · Sr. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,000

Underlying: Common Stock · 42,000 shares

Expires 2030-06-18

F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-19-007978 · edgar.xml · derivative · entry 1

Wright Richard M. · CIK 0001646423 · Sr. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2029-06-19

F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-18-008566 · edgar.xml · derivative · entry 1

Wright Richard M. · CIK 0001646423 · Sr. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2028-06-13

F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

SEC source: 0001179110-17-009157 · edgar.xml · derivative · entry 1

Wright Richard M. · CIK 0001646423 · Sr. VP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2027-06-15

F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2 · derivative.exercise_date: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.